Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database

Campos-Alberto, Eduardo; Hirose, Tomohiro; Napatalung, Lynne; Ohyama, Manabu

doi:10.1111/1346-8138.16615

Cited by 15 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other studies have used the JMDC database to calculate the prevalence of specific diseases for the whole of Japan [ 23 , 24 ]. In this study, the prevalence ( P d,t,r,a,s ) of the target disease ( d ) in each prefecture or municipality ( r ) by age ( a :0–19, 20–39, 40–64, and 65–74 years) and sex ( s ) groups for each year ( t ) were calculated according to eqs.…”

Section: Methodsmentioning

confidence: 99%

Annual prevalence of non-communicable diseases and identification of vulnerable populations following the Fukushima disaster and COVID-19 pandemic

Murakami

Nomura

2023

International Journal of Disaster Risk Reduction

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Annual prevalence of non-communicable diseases and identification of vulnerable populations following the Fukushima disaster and COVID-19 pandemic

Murakami

Nomura

2023

International Journal of Disaster Risk Reduction

View full text Add to dashboard Cite

“…Population figures were taken from the Japanese 2020 Population Census 37 and AA prevalence and severity figures were taken from recent Japanese studies. 3,5 Self-pay rate for prescribed medication was assumed to be 30% of total medication costs, the norm for residents under 70 years of age in Japan. 38 The participation rates of each daily activity were taken from Statistics Bureau of Japan data.…”

Section: Nationwide Estimationmentioning

confidence: 99%

“…The lifetime incidence of AA has been estimated as approximately 2% worldwide 2 . A Japanese claims database study found that the prevalence of AA has gradually risen from 0.16% in 2012 to 0.27% in 2019 3 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Economic burden of alopecia areata: A study of direct and indirect cost in Japan using real‐world data

Ohyama

Kamei

Yuasa

et al. 2023

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Alopecia area (AA) is a common autoimmune disorder, characterized by hair loss. Although its impact on quality of life is fairly well understood, studies on the economic impact of AA are limited. The aim of this study was to quantify the personal and nationwide economic burden of AA in Japan. Data were drawn from the Adelphi AA Disease Specific Programme (DSP)™, a real‐world, cross‐sectional survey with retrospective data collection, of Japanese physicians and patients with AA. The study was conducted in 2021, before the approval of Janus kinase inhibitors for AA. Physicians and their consulting AA patients completed questionnaires regarding disease severity, treatment, and AA‐related costs. The Work Productivity and Activity Impairment questionnaire was used to evaluate the impact of AA on patients' work and activity. Nationwide estimates of cost and productivity loss were extrapolated from collected patient data. A total of 50 physicians provided data on 235 patients; 58.7% were female, mean ± SD age was 41.1 ± 11.8 years, and mean physician‐estimated scalp hair loss was 40.4% ± 30.2%. Prescription medication use was high (92.3% of patients), but the use of over‐the‐counter medication was low, at 8.7%. Mean cost to patients for medication was ¥ 4263 (US$ 32.42) per month. Productivity while at work (presenteeism) was significantly impaired (23.9% ± 25.7%), but absenteeism was low (0.9% ± 2.8%). The total nationwide cost of AA was estimated at 112.7 billion yen (US$ 857 million), of which 88.1 billion yen (78.2%) was due to productivity loss. Over 2 million days per year of activity time were estimated to be lost due to AA. Thus, despite not being a physically limiting disease, AA has a significant impact in terms of cost and time, both on a personal and national level. These data highlight the need for more targeted interventions to reduce the effects of AA on the Japanese economy.

show abstract

“…The incidence varies from 20.9 to 26.0 per 100,000 person‐years 8,9 . Prevalence estimates range from 0.04% to 6.7% 3,10,11 . Differences in estimates are likely attributed to differences in methodology, study design and population cohort.…”

Section: Introductionmentioning

confidence: 99%

Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data

Sinclair

Eisman

Song³

et al. 2023

Aust J Dermatology

View full text Add to dashboard Cite

BackgroundAlopecia areata (AA) is a common immune‐mediated non‐scarring hair loss, with a worldwide incidence between 0.57% and 3.8%. The incidence and prevalence of AA in the Australian general population have not been previously reported.ObjectiveTo describe the incidence and prevalence of AA in Australia using primary care data. A secondary objective was to identify common demographic characteristics, comorbidities and treatment patterns among Australians living with AA.MethodsWe analysed electronic health record data captured from a national clinical practice management software over a 10‐year index period between 2011 and 2020 calendar years, inclusive. The incidence of new‐onset AA and the prevalence of active records with AA were estimated. Differences in incidence by sociodemographic groups, and patterns of treatment were also evaluated.ResultsThere were 976 incident AA records. The incidence of new‐onset AA in the total study cohort was 0.278 per 1000 person‐years (95% CI 0.26–0.295). By age, the incidence was highest in the 19‐ to 34‐year‐old age bracket (0.503 per 1000 person‐years: 95% CI 0.453–0.554). AA incidence was lower among females than males (IRR 0.763, p < 0.001, 95% CI 0.673–0.865). Among active records, 520 were prevalent AA records. AA point prevalence at 31/12/2020 was 0.13% (1.26 per 1000 persons; 95% CI 1.15–1.37).ConclusionThis is the first study to describe the epidemiology (incidence and point prevalence) and management of AA in the Australian primary health‐care population through large‐scale database analysis. Incidence and prevalence findings were consistent with earlier estimates from other regions.

show abstract

Prevalence, comorbidities, and treatment patterns of Japanese patients with alopecia areata: A descriptive study using Japan medical data center claims database

Cited by 15 publications

References 55 publications

Annual prevalence of non-communicable diseases and identification of vulnerable populations following the Fukushima disaster and COVID-19 pandemic

Annual prevalence of non-communicable diseases and identification of vulnerable populations following the Fukushima disaster and COVID-19 pandemic

Economic burden of alopecia areata: A study of direct and indirect cost in Japan using real‐world data

Incidence and prevalence of alopecia areata in the Australian primary care setting: A retrospective analysis of electronic health record data

Contact Info

Product

Resources

About